Why Testosterone Matters for Women: Hormone Therapy, Menopause, Libido, and Modern Women's Health

What Testosterone Does in the Female Body

Testosterone is not a hormone women happen to have in small amounts. Women produce testosterone in the ovaries and adrenal glands at levels that, while lower than in men, are physiologically essential. A healthy premenopausal woman in her 20s maintains a serum total testosterone of roughly 0.5 to 1.7 nmol/L, and that range supports a wide range of functions that have nothing to do with masculinization [1].

Energy Metabolism and Body Composition

Testosterone binds androgen receptors in skeletal muscle and drives protein synthesis. In women, this means it contributes to lean mass, resting metabolic rate, and the capacity to recover from exercise. Research published in the Journal of Clinical Endocrinology and Metabolism (JCEM) confirmed that women with bilaterally removed ovaries, who lose roughly 50% of circulating testosterone acutely, show measurable declines in lean body mass within 12 months compared with naturally menopausal controls [2].

Bone Health

Androgens stimulate osteoblast activity independently of estrogen. The Study of Women's Health Across the Nation (SWAN) followed 2,961 women across the menopausal transition and found that lower free androgen index was independently associated with lower lumbar spine bone mineral density, even after adjusting for estradiol [3].

Cognitive Function and Mood

Androgen receptors are expressed in the prefrontal cortex, hippocampus, and amygdala. Observational data suggest women with lower endogenous testosterone scores higher on measures of depressive symptoms and cognitive fatigue, though causality is difficult to isolate [4]. This does not mean testosterone is a depression treatment. The relationship is complex and bidirectional.

How Testosterone Levels Change Across a Woman's Life

Unlike estrogen, which drops precipitously at menopause, testosterone follows a slower arc. The decline begins in the mid-20s and continues at approximately 1% per year. By age 45, many women have half the testosterone they had at 20, even before their last menstrual period [5].

The Oral Contraceptive Effect

This is one of the most underappreciated drivers of low testosterone symptoms in younger women. Combined oral contraceptives increase hepatic production of SHBG by two to fourfold. Because only free (unbound) testosterone is biologically active, a high SHBG level can produce symptomatic androgen deficiency even when total testosterone is measured as "normal." A 2006 study in the Journal of Sexual Medicine (N=124) found that women who had ever used oral contraceptives had persistently elevated SHBG and lower free testosterone scores compared with never-users, and this persisted for months after stopping the pill [6].

Surgical Menopause: The Acute Drop

Bilateral oophorectomy removes the primary ovarian source of testosterone. Women who undergo this procedure before natural menopause experience an abrupt hormonal transition that natural menopause does not replicate. The 2019 Global Consensus Position Statement on Testosterone for Women, endorsed by the International Menopause Society, the Endocrine Society, and eight other professional societies, specifically highlights surgically menopausal women as a high-priority group for testosterone evaluation [7].

Testosterone and Female Sexual Function

Hypoactive sexual desire disorder (HSDD) is defined as persistently low sexual desire that causes personal distress. Testosterone is the only hormone with a strong, replicated evidence base for improving HSDD in postmenopausal women [7].

What the Clinical Trials Show

The APHRODITE trial (N=814 naturally menopausal women) tested a testosterone patch delivering 300 mcg per day versus placebo over 52 weeks. Women in the active arm reported a statistically significant increase in satisfying sexual events (mean increase of 2.1 per 4 weeks vs. 0.98 for placebo, P<0.001) and significant improvements in desire and arousal scores [8].

A Cochrane systematic review published in 2019 analyzed 46 randomized controlled trials involving 8,480 women and concluded that testosterone therapy was associated with improved sexual function across multiple domains including desire, arousal, orgasm, and pleasure, with the strongest effect at physiological rather than supraphysiological dosing [9].

HSDD Is Not "Just Stress"

Clinicians sometimes attribute low desire in women entirely to relationship or psychological factors. That framing is incomplete. The biologic substrate of desire includes androgen signaling, and a woman whose free testosterone has been suppressed by years of oral contraceptive use or by surgical menopause deserves a hormonal evaluation alongside any psychological assessment. The 2019 Consensus Statement states: "There is a biologic basis for the role of testosterone in female sexual function, and its deficiency is associated with reduced sexual desire." [7]

Premenopausal Women and HSDD

The evidence base for testosterone in premenopausal women with HSDD is smaller but growing. A 2014 systematic review in the European Journal of Endocrinology found that transdermal testosterone produced meaningful improvements in desire scores in premenopausal women, though sample sizes were limited and long-term data were sparse [10]. Current guidelines recommend against routine testosterone therapy in premenopausal women outside of clinical settings with careful monitoring, given the limited safety data across reproductive years.

How Testosterone Therapy Is Delivered in Women

No testosterone product is currently FDA-approved specifically for women in the United States. This is a regulatory gap, not a safety signal. The 2019 Global Consensus Position Statement and the Endocrine Society's Clinical Practice Guidelines both acknowledge that off-label use of male-formulated or compounded transdermal products is clinically appropriate when used at doses targeting female physiological ranges [7, 11].

Transdermal Gels and Creams

The most commonly used approach involves applying a fraction of a male-dose testosterone gel (such as AndroGel 1% or compounded testosterone cream) to achieve serum total testosterone levels within or just above the normal premenopausal female range (0.5 to 1.7 nmol/L). Typical female doses range from 0.5 to 2 mg per day applied to the inner arm or thigh, compared with 50 to 100 mg per day in men.

Pellet Implants: A Note of Caution

Subcutaneous pellet implants deliver testosterone continuously over three to six months. While popular in some concierge medicine settings, pellets carry a higher risk of supraphysiological testosterone levels because the dose cannot be adjusted once implanted. The Endocrine Society's 2014 guideline recommends against any formulation that cannot be adjusted or discontinued if adverse effects arise [11].

Monitoring Protocol

Women using testosterone therapy should have serum total testosterone and SHBG measured at baseline, then at 6 weeks after initiation to confirm physiological levels are achieved, and every 6 months thereafter. Hematocrit should be checked annually. The treating clinician should document distress scores (using validated tools such as the Female Sexual Distress Scale or FSDS-R) at baseline and every 3 to 6 months to confirm meaningful clinical benefit.

Testosterone, Cardiovascular Risk, and Breast Cancer: What the Evidence Actually Says

These are the two concerns most commonly raised when women ask about testosterone therapy. Both deserve careful examination rather than reflexive alarm.

Cardiovascular Effects

A 2017 meta-analysis published in the Lancet Diabetes and Endocrinology (covering 16 trials, N=1,957 women) found no significant adverse effect of testosterone therapy on lipid profiles, blood pressure, or cardiovascular events at physiological doses over treatment periods up to 2 years [12]. Supraphysiological dosing does lower HDL cholesterol, which is one reason targeting physiological levels matters clinically. Oral testosterone formulations, which are rarely used in women, undergo first-pass hepatic metabolism and may produce less favorable lipid effects than transdermal delivery.

Breast Cancer Risk

The 2019 Global Consensus Statement concluded: "There are no data to support an increased risk of breast cancer with testosterone therapy in women." [7] Observational data from the large Nurses' Health Study suggested that higher endogenous androgens were associated with modestly increased breast cancer risk, but this association does not directly translate to exogenous testosterone therapy at physiological doses [13]. Women with a personal history of hormone-receptor-positive breast cancer should discuss testosterone therapy with their oncologist; current data are insufficient to make a blanket recommendation in either direction for this subgroup.

Diagnosing Low Testosterone in Women: What Labs to Order and How to Read Them

There is no universally agreed cutoff for "low" testosterone in women because laboratories use assays developed for male ranges, and reference intervals vary widely. The Endocrine Society recommends against diagnosing androgen deficiency in women based on a single total testosterone value alone [11].

The Right Tests

A useful panel includes total testosterone by liquid chromatography-mass spectrometry (LC-MS/MS, the most accurate method for female-range values), SHBG, free testosterone (calculated or by equilibrium dialysis), and DHEA-S (a marker of adrenal androgen production). Immunoassay-based testosterone tests commonly used in routine labs are unreliable at the low concentrations seen in women and may underestimate or overestimate true levels by 30% or more [11].

Timing of the Draw

Testosterone in women peaks in the morning during the follicular phase (days 8 to 12 of the menstrual cycle in premenopausal women). Drawing blood in the afternoon or during the luteal phase may produce a result that appears low but is physiologically normal. Postmenopausal women can have their blood drawn at any time, as cyclical variation is absent.

Symptom-Guided Diagnosis

Because labs are imperfect, the 2019 Consensus Statement recommends a symptom-guided approach. A woman with low libido causing personal distress, unexplained fatigue, and difficulty with arousal, whose serum testosterone is in the lower quartile of the premenopausal range (below approximately 0.4 nmol/L by LC-MS/MS), is a reasonable candidate for a therapeutic trial of transdermal testosterone regardless of whether she falls below an arbitrary "deficiency" threshold [7].

Testosterone in the Context of Full Hormone Therapy for Menopausal Women

Menopause hormone therapy (MHT) typically combines estrogen with progestogen in women with an intact uterus. Testosterone is increasingly considered a third component of a complete hormonal regimen, particularly for women who continue to experience low libido, fatigue, or mood symptoms despite optimized estrogen therapy.

Does Estrogen Adequacy Come First?

Yes. Estrogen deficiency itself causes vaginal dryness, dyspareunia, and mood changes that can mimic or compound low-testosterone symptoms. Before adding testosterone, clinicians should confirm that estrogen therapy (oral, patch, or vaginal) is optimized. A trial of adequate estrogen replacement lasting at least 8 to 12 weeks is a reasonable first step before attributing residual symptoms to androgen deficiency [7].

Testosterone Alongside Estrogen and Progesterone

In women who have optimized estrogen and still experience HSDD or persistent fatigue, adding transdermal testosterone at a dose targeting serum levels of 0.5 to 1.7 nmol/L is supported by the 2019 Global Consensus and the British Menopause Society guidelines [7, 14]. The SWAN study reported that women using combined estrogen-androgen therapy had better self-reported quality of life scores than those on estrogen alone at the 5-year follow-up [3].

Side Effects and When to Reduce the Dose

At physiological doses, androgenic side effects in women are uncommon but real. The most frequently reported are mild acne (in approximately 5 to 10% of users) and fine facial hair growth. These are dose-dependent and typically resolve within 4 to 8 weeks of dose reduction [9].

What Is Not Expected at Physiological Doses

Clitoral enlargement, voice deepening, and significant scalp hair loss are associated with supraphysiological testosterone levels, not with the doses recommended for HSDD treatment. If any of these occur, the dose should be reduced immediately and serum testosterone rechecked.

Monitoring Schedule in Practice

Baseline labs, then 6-week recheck, then every 6 months. If total testosterone by LC-MS/MS exceeds 1.7 nmol/L on repeat testing, reduce the dose by 25 to 50% and recheck in 6 weeks. Do not rely on symptom resolution alone as a sign that levels are in range.

Frequently Asked Questions